Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Robinhood Markets, Inc. (HOOD) vs Mesoblast Limited (MESO) Price & Performance

Robinhood Markets, Inc.Trade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Robinhood Markets, Inc. vs Mesoblast Limited — how do they compare? Robinhood Markets, Inc. trades at $95.03 (market cap $84.86B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Robinhood Markets, Inc. is far larger — about 38.4× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.

HOODMESO
Market Cap
$84.86B$2.21B
Sector
TechnologyTechnology
52-Week High
$152.46$20.96
52-Week Low
$65.16$12.88
Enterprise Value
$91.40B$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Robinhood Markets, Inc.

Robinhood Markets (HOOD) trades at $95.19, up 0.71% on the day, with the stock showing strong fundamental momentum despite a bearish technical signal. The company reported impressive 2025 results with $4.47B revenue and $1.88B net income, representing 42% net margins. Recent Q2 2026 earnings beat expectations with $0.62 EPS versus $0.44 expected, though technical indicators show resistance near $95-97 levels with RSI suggesting potential overbought conditions.

HOOD presents a compelling growth story with 73% analyst buy ratings and a $123.46 consensus price target representing 30% upside potential. Key opportunities include international expansion and product diversification beyond crypto, while risks involve competitive pressures and market volatility sensitivity. The company's transition to profitability and strong cash flow generation support long-term bullish thesis despite near-term technical headwinds.

Mesoblast Limited

MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.

Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Robinhood Markets, Inc.

Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.

Read more on HOOD

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO